Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

1st Mar 2022 14:35

RNS Number : 2423D
Ideagen PLC
01 March 2022
 

1 March 2022

 

 

Ideagen PLC

("Ideagen" "the Company" or "the Group")

 

Director/PDMR Shareholding

 

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management software to highly regulated industries, announces that Alan Carroll, a Non-Executive Director and PDMR, yesterday sold 3,274 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") from his ISA at a price of 221.0 pence per Ordinary Share, and his wife's ISA acquired 3,274 Ordinary Shares at a price of 221.8 pence per Ordinary Share (the "Sale and Purchase").

 

As a result of the Sale and Purchase, Mr Carroll and his Persons Closely Associated ("PCAs")'s beneficial interest in Ideagen remains unchanged at 204,463 Ordinary Shares, representing 0.07% of the Company's issued share capital.

 

 

Enquiries:

Ideagen plc

01629 699 100

Ben Dorks, Chief Executive Officer

 

Emma Hayes, Chief Financial Officer

 

 

 

 

Canaccord Genuity Limited (Nomad)

020 7523 8000

Simon Bridges

 

Georgina McCooke

 

 

 

finnCap Limited

020 7220 0500

Henrik Persson/James Thompson

 

Alice Lane

 

 

 

 

Numis Securities Limited

0207 260 1267

Simon Willis

 

Joshua Hughes

 

 

 

FTI Consulting

020 3727 1000

Jamie Ricketts

ideagen@fticonsulting.com

Dwight Burden

 

Valerija Cymbal

 

 

 

About Ideagen plc

Ideagen's software helps companies comply with regulation and manage risk.

Ideagen is a leader in the +$30 billion regulatory and compliance software market, serving highly regulated industries such as life sciences, healthcare, banking and finance and insurance. 

More than 8,000 customers use Ideagen's software, including 9 of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of leading pharmaceutical firms.

Ideagen has a diversified customer base including blue chip, global brands such as Heineken, British Airways, BAE, Aggreko, US Navy, Bank of New York and Johnson Matthey, as well as 250 hospitals across the UK and US.

Ideagen is headquartered in the UK, listed on the London Stock Exchange AIM market (Ticker: IDEA.L), and has key hubs in the UK, USA, Middle East and South East Asia. For further information please visit www.ideagen.com.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Alan Carroll

2.

Reason for the Notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Ideagen plc

b)

LEI

213800KS1MLITOVNYC85

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Ordinary Shares

Identification code

GB00B0CM0C50

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Volume(s) Price (pence)

3,274 221.0

d)

Aggregated information:

· Aggregated volume

· Price

 

n/a

e)

Date of the transaction

28 February 2022

f)

Place of the transaction

London Stock Exchange, AIM (XLON)

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Louise Carroll

2.

Reason for the Notification

a)

Position/status

PCA of Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Ideagen plc

b)

LEI

213800KS1MLITOVNYC85

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Ordinary Shares

Identification code

GB00B0CM0C50

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Volume(s) Price (pence)

3,274 221.8

d)

Aggregated information:

· Aggregated volume

· Price

 

n/a

e)

Date of the transaction

28 February 2022

f)

Place of the transaction

London Stock Exchange, AIM (XLON)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFZGGFDMMGZZM

Related Shares:

IDEA.L
FTSE 100 Latest
Value8,602.92
Change0.00